Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Tumor Checkpoint Controller Also In Early Clinical Studies
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
You may also be interested in...
Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.